secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001558370-24-000877
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IRADIMED reports record Q4 revenue $17.5M (+17.4%); initiates quarterly dividend; FY24 guidance $72-74M
--------------------------------------------------------------------------------

- Record Q4 2023 revenue $17.5M (+17.4% YoY); GAAP diluted EPS $0.36 vs $0.29, non-GAAP $0.39 vs $0.32.
- Full-year 2023 revenue $65.6M (+23% YoY); GAAP EPS $1.35, non-GAAP EPS $1.48; operating income $20.0M (+28.2%).
- Guidance Q1 2024: rev $17.0-17.3M, GAAP EPS $0.29-0.31, non-GAAP $0.33-0.35. FY2024: rev $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62.
- CEO announces initiation of a quarterly dividend in 2024 (amount and record date not specified in release).
- Operating cash flow for FY2023 $13.5M vs $10.0M; expects ~$13M capex for new Orlando facility in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/0001558370-24-000877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/irmd-20240208x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer